Appointment of Internal Auditors for the FY 2026-27
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Akums Drugs reported FY2025-26 standalone revenue of ₹13,487 million, essentially flat versus FY25's ₹13,118 million (just 2.8% growth). However, profit after tax dropped significantly to ₹1,116 million from ₹1,610 million in the prior year—a 31% decline. The board recommended a total dividend of ₹3 per share (₹1 final + ₹2 special), with record date July 3, 2026. The auditors issued an unmodified (clean) opinion. An 'Emphasis of Matter' paragraph highlights an ongoing Income Tax Department search and seizure operation from January 2025 and subsequent show cause notices under section 158BC, though the financial impact remains unquantifiable. Exceptional items of ₹65.19 million were recognized due to new labour code implementation and VDA arrears. Mahajan & Aibara LLP was appointed as internal auditors for FY2026-27, replacing the prior firm. The company also saw a change in HR leadership.
The sharp PAT decline despite stable revenues signals margin compression and higher costs, which could pressure the stock. The ongoing IT tax proceedings and exceptional items add uncertainty. However, the dividend payout and clean audit opinion provide some comfort to investors.